Regulatory Tool

FDA Status Tracker

FDA regulatory status for peptide compounds changes through Federal Register actions, Pharmacy Compounding Advisory Committee reviews, and category reassignments. PSI tracks each change against the federal primary source and updates this page when the regulatory record moves.

Why most peptides are not FDA approved

Most peptides are not FDA approved because the approval process costs between $500 million and $2 billion and typically requires a patent strong enough to fund the trial. Most peptides cannot be patented.

Read the full editorial →

The table below tracks the current regulatory status of every peptide PSI covers: FDA-approved compounds, compounds allowed through pharmacy compounding, and compounds under active reclassification review. Status changes over time, sometimes quickly.


PreclinicalAnimal StudiesHuman TrialsFDA Approved

Showing 147 of 147 compounds

CompoundAccessDetails
5-Amino-1MQ
Compoundable(Under Review)
+
Ac-SDKP
Compoundable(Under Review)
+
ACE-031
Compoundable(Under Review)
+
Adipotide (FTPP)
Compoundable(Under Review)
+
AHK-Cu (Copper Tripeptide)
Compoundable(Under Review)
+
Alpha-1 Antitrypsin Peptide (VIRIP)
Compoundable(Under Review)
+
Angiotensin-(1-7)
Compoundable(Under Review)
+
AOD-9604
Not Compoundable(Voted Against)
+
Apelin
Compoundable(Under Review)
+
Apelin-13
Compoundable(Under Review)
+
ARA-290
Compoundable(Under Review)
+
Argireline (Acetyl Hexapeptide-3)
Compoundable(Under Review)
+
B7-33
Compoundable(Under Review)
+
Beta-Glucan Peptide
Compoundable(Under Review)
+
Bimagrumab
Compoundable(Under Review)
+
Biomimetic Peptide 14
Compoundable(Under Review)
+
BNP (Brain Natriuretic Peptide)
Compoundable(Under Review)
+
BPC-157
Compoundable(Under Review)
+
BPC-157 Arginine Salt
Compoundable(Under Review)
+
BPC-157/TB-500 Blend
Compoundable(Under Review)
+
CagriSema
Compoundable(Under Review)
+
Cartalax
Compoundable(Under Review)
+
Catestatin
Compoundable(Under Review)
+
Cathelicidin Peptides
Compoundable(Under Review)
+
Cerebrolysin
Compoundable(Under Review)
+
CGRP (Calcitonin Gene-Related Peptide)
Compoundable(Under Review)
+
CJC-1295
Not Compoundable(Voted Against)
+
CJC-1295 without DAC (Mod GRF 1-29)
Compoundable(Under Review)
+
Copeptin
Compoundable(Under Review)
+
Copper Peptides
Compoundable(Under Review)
+
Cortexin
Compoundable(Under Review)
+
Cortistatin
Compoundable(Under Review)
+
DAHK Peptide
Compoundable(Under Review)
+
Davunetide (NAP/AL-108)
Compoundable(Under Review)
+
Decorin
Compoundable(Under Review)
+
Defensins
Compoundable(Under Review)
+
Degarelix
FDA-Approved(Prescription)
+
Dihexa
Compoundable(Under Review)
+
DSIP
Compoundable(Under Review)
+
Enclomiphene
Compoundable(Under Review)
+
Epitalon
Compoundable(Under Review)
+
Exenatide
FDA-Approved(Prescription)
+
Follistatin
Compoundable(Under Review)
+
FOXO4-DRI
Compoundable(Under Review)
+
Galanin
Compoundable(Under Review)
+
GDF-11 (Growth Differentiation Factor 11)
Compoundable(Under Review)
+
GDF-15
Compoundable(Under Review)
+
GHK
Compoundable(Under Review)
+
GHK-Cu
Compoundable(Under Review)
+
GHRP-2
Not Compoundable(Insufficient Data)
+
GHRP-6
Not Compoundable(Insufficient Data)
+
GIP (Glucose-Dependent Insulinotropic Polypeptide)
Compoundable(Under Review)
+
Glucagon
FDA-Approved(Prescription)
+
Glycine-Proline-Glutamate (GPE)
Compoundable(Under Review)
+
GnRH Agonist Peptides
FDA-Approved(Prescription)
+
Gonadorelin
FDA-Approved(Prescription)
+
HCG (Human Chorionic Gonadotropin)
FDA-Approved(Prescription)
+
Hepcidin
Compoundable(Under Review)
+
Hexarelin
Compoundable(Under Review)
+
HGH Fragment 176-191
Compoundable(Under Review)
+
Humanin
Compoundable(Under Review)
+
IGF-1 DES
Compoundable(Under Review)
+
IGF-1 LR3
Compoundable(Under Review)
+
Ipamorelin
Not Compoundable(Voted Against)
+
Irisin
Compoundable(Under Review)
+
Khavinson Peptide Bioregulators
Compoundable(Under Review)
+
Kisspeptin
Not Compoundable(Voted Against)
+
Kisspeptin-54 (Metastin)
Compoundable(Under Review)
+
Klotho Peptide
Compoundable(Under Review)
+
KPV
Compoundable(Under Review)
+
Lactoferricin
Compoundable(Under Review)
+
Larazotide Acetate
Compoundable(Under Review)
+
Liraglutide
FDA-Approved(Prescription)
+
Livagen
Compoundable(Under Review)
+
LL-37
Compoundable(Under Review)
+
Maridebart Cafraglutide (MariTide)
Compoundable(Under Review)
+
Matrixyl (Palmitoyl Pentapeptide-4)
Compoundable(Under Review)
+
Mazdutide
Compoundable(Under Review)
+
Mechano Growth Factor (MGF)
Compoundable(Under Review)
+
Melanocyte-Stimulating Hormone (α-MSH)
Compoundable(Under Review)
+
Melanotan I (Afamelanotide)
Compoundable(Under Review)
+
Melanotan II
Compoundable(Under Review)
+
MK-677 (Ibutamoren)
Not Compoundable(Voted Against)
+
MOTS-c
Compoundable(Under Review)
+
Myostatin Inhibitor Peptides
Compoundable(Under Review)
+
N-Acetyl Selank
Compoundable(Under Review)
+
N-Acetyl Semax
Compoundable(Under Review)
+
Neuromedin U
Compoundable(Under Review)
+
Neuropeptide Y (NPY)
Compoundable(Under Review)
+
NMN (Nicotinamide Mononucleotide)
Compoundable(Under Review)
+
Noopept (GVS-111)
Compoundable(Under Review)
+
Orexin-A (Hypocretin-1)
Compoundable(Under Review)
+
Osteocalcin (Uncarboxylated)
Compoundable(Under Review)
+
Oxytocin
FDA-Approved(Prescription)
+
P21 (NSI-189 Peptide Fragment)
Compoundable(Under Review)
+
p28 (Azurin Peptide Fragment)
Compoundable(Under Review)
+
p53 Peptides
Compoundable(Under Review)
+
Palmitoyl Tripeptide-1
Compoundable(Under Review)
+
Palmitoyl Tripeptide-5
Compoundable(Under Review)
+
Pasireotide (SOM230)
FDA-Approved(Prescription)
+
PEG-MGF
Compoundable(Under Review)
+
Pemvidutide
Compoundable(Under Review)
+
Pentagastrin
Compoundable(Under Review)
+
Pentosan Polysulfate (PPS)
FDA-Approved(Prescription)
+
Pinealon
Compoundable(Under Review)
+
Plerixafor
FDA-Approved(Prescription)
+
Pramlintide (Symlin)
FDA-Approved(Prescription)
+
Protegrin-1
Compoundable(Under Review)
+
PT-141 (Bremelanotide)
FDA-Approved(Prescription)
+
Rapamycin/mTOR Peptide Inhibitors
Compoundable(Under Review)
+
Relaxin-2 (Serelaxin)
Compoundable(Under Review)
+
Retatrutide
Compoundable(Under Review)
+
Selank
Compoundable(Under Review)
+
Semaglutide
FDA-Approved(Prescription)
+
Semax
Compoundable(Under Review)
+
Senolytic Peptide Conjugates
Compoundable(Under Review)
+
Sermorelin
Compoundable(Under Review)
+
Setmelanotide
FDA-Approved(Prescription)
+
SHLP2 (Small Humanin-Like Peptide 2)
Compoundable(Under Review)
+
SHLP6
Compoundable(Under Review)
+
SNAP-8 (Acetyl Octapeptide-3)
Compoundable(Under Review)
+
SS-31 (Elamipretide)
Compoundable(Under Review)
+
Substance P
Compoundable(Under Review)
+
Survodutide
Compoundable(Under Review)
+
TA-65 (Cycloastragenol)
Compoundable(Under Review)
+
TB-500
Compoundable(Under Review)
+
Teixobactin
Compoundable(Under Review)
+
Tesamorelin
FDA-Approved(Prescription)
+
Tesofensine
Compoundable(Under Review)
+
Tetracosactide (Cosyntropin/Synacthen)
Compoundable(Under Review)
+
Thymalfasin (Thymosin Alpha-1 Synthetic)
Compoundable(Under Review)
+
Thymalin
Compoundable(Under Review)
+
Thymogen
Compoundable(Under Review)
+
Thymopoietin
Compoundable(Under Review)
+
Thymosin Alpha-1
Not Compoundable(Voted Against)
+
Thymosin Beta-10
Compoundable(Under Review)
+
Thymosin Beta-4
Compoundable(Under Review)
+
Thymulin (FTS/ZnFTS)
Compoundable(Under Review)
+
Tirzepatide
FDA-Approved(Prescription)
+
TRIM (Thyrotropin-Releasing Hormone Analog)
Compoundable(Under Review)
+
Triptorelin
FDA-Approved(Prescription)
+
Trofinetide (Daybue)
FDA-Approved(Prescription)
+
Ularitide (Urodilatin)
Compoundable(Under Review)
+
Vesugen
Compoundable(Under Review)
+
Vilon
Compoundable(Under Review)
+
VIP (Vasoactive Intestinal Peptide)
Compoundable(Under Review)
+
α-AIB (Alpha-Aminoisobutyric Acid Peptides)
Compoundable(Under Review)
+

Access state definitions

FDA Approved. Prescription medicines that completed the full FDA regulatory process.

Compoundable. A physician can currently have the compound prepared through a licensed specialty pharmacy under the FDA's 503A framework. Under Review: evaluated for formal 503A inclusion. On 503A Bulks List: evaluation complete and the compound has been formally authorized for compounding.

Not Compoundable. The 503A pathway is currently closed. Safety Risk: the FDA evaluated the compound and identified safety concerns that preclude compounding. Insufficient Data: the compound was nominated for evaluation but the nomination did not include sufficient information for the FDA to act. Voted Against: the Pharmacy Compounding Advisory Committee reviewed the compound and voted against recommending it for compounding.


Sources: PubMed, Federal Register, FDA advisory committee records. Full methodology at Editorial Standards.

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.